Drug Profile
LEAC 102
Alternative Names: LEAC-102Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Taiwan Biotech Co Ltd
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastrointestinal cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Taiwan (PO, Capsule)
- 21 Jul 2016 Preclinical trials in Gastrointestinal cancer in Taiwan (PO)
- 21 Jul 2016 Taiwan Leader Biotech plans a phase I/IIa trial for Gastrointestinal cancer in Taiwan and US (NCT02826837)